



## Curriculum Vitae

Personal information **Karin Fjordén**

### Work experience

---

1. Employer: Skåne University Hospital, Oncology Unit, hourly employment as physician (from September 2023, ongoing)
2. Employer: Medical Products Agency
  - Start date: 092021
  - End date: Ongoing
  - Position: Clinical assessor
  - Activities:
  - Country: Sweden
3. Employer: Skåne University Hospital
  - Start date: 052016
  - End date: 092021
  - Position: Clinical oncologist
  - Activities: Specialist in Medical and Radiation Oncology
  - Country: Sweden
4. Employer: Skåne University Hospital
  - Start date: 062007
  - End date: 052016
  - Position: Residency in Medical and Radiation Oncology
  - Activities: In parallel PhD student November 2008 \_ March 2015, Department of Oncology, Lund University
  - Country: Sweden
5. Employer: Kalmar County Hospital
  - Start date: 082005
  - End date: 052007
  - Position: Internship
  - Activities:
  - Country: Sweden

### Education and training

---

1. Subject: Skåne University Hospital
  - Start date: 062007
  - End date: 052016
  - Qualification: Specialist training in Medical and Radiation Oncology
  - Organisation:
  - Country: Sweden
2. Subject: Department of Oncology, Lund University
  - Start date: 112008
  - End date: 032015
  - Qualification: Doctor of Medicine (PhD)
  - Organisation:
  - Country: Sweden
3. Subject: Kalmar County Hospital
  - Start date: 082005
  - End date: 052007
  - Qualification: License to Practice Medicine
  - Organisation:
  - Country: Sweden
4. Subject: Lund University
  - Start date: 081999
  - End date: 062005
  - Qualification: University Medical Degree (MD)
  - Organisation:
  - Country: Sweden

### Additional information

---

#### Publications

1. The dual role of CD70 in B<sub>2</sub> cell lymphomagenesis. Nie M, Ren W, Ye X, Berglund M, Wang X, Fjordén K, Du L, Giannoula Y, Lei D, Su W, Li W, Liu D, Linderöth J, Jiang C, Bao H, Jiang W, Huang H, Hou Y, Zhu S, Enblad G, Jerkeman M, Wu K, Zhang H, Amini RM, Li ZM, Pan\_Hammarström Q. Clin Transl Med. 2022 Dec;12(12):e1118. doi: 10.1002/ctm2.1118.
2. Idelalisib in relapsed/refractory diffuse large B<sub>2</sub> cell lymphoma: results from a Nordic Lymphoma Group phase II trial; Fjordén K, Ekberg S, Kuric N, Smedby KE, Lagerlöf I, Larsen TS, Jørgensen JM, de Nully Brown P, Jerkeman M. Br J Haematol; .Epub 2021 Aug 25.doi:10.1111/bjh.17792.
3. Plasma Immunoprofiling of Patients with High\_risk Diffuse Large B<sub>2</sub> cell Lymphoma; a Nordic Lymphoma Group Study; Pauly F\*, Fjordén K\*, Leppä S, Holte H, Björkholm M, Fluge Ø, Møller Pedersen L, Eriksson M,

Isinger\_Ekstrand A, Borrebaeck C, Jerkeman M, Wingren C. \* joint first author, Blood Cancer J. 2016 Nov 18;6(11):e501

4. Deregulation of COMMD1 is Associated with Poor Prognosis in Diffuse Large B\_cell Lymphoma; Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, Delabie J, Karjalainen\_Lindsberg ML, Björkholm M, Fluge Ø, Pedersen LM, Fjordén K, Jerkeman M, Eriksson M, Hautaniemi S, Leppä S, PLoS One. 2014 March 9(3); e91031
5. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Diffuse Large B\_cell Lymphoma Cell Lines to CHOP\_induced Cell Death; Ageberg M, Rydström K, Relander T, Drott K, Am J Transl Res. 2013 5(2):170\_83
6. High Serum Vascular Endothelial Growth Factor Level is an Adverse Prognostic Factor for High\_risk Diffuse Large B\_cell Lymphoma Patients Treated with Dose\_dense Chemoimmunotherap; Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge O, Pedersen LM, Rydström K, Jerkeman M, Eriksson M, Leppä S, Eur J Haematol. 2012 Nov; 89(5):395\_402
7. Gene Expression Profiling Indicates that Immunohistochemical Expression of CD40 is a Marker of an Inflammatory Reaction in the Tumour Stroma of Diffuse Large B\_cell Lymphoma; Rydström K, Joost P, Ehinger M, Edén P, Jerkeman M, Cavallin\_Ståhl E, Linderöth J, Leuk Lymphoma. 2012 Sept; 53(9):1764\_8
8. Inhibition of Geranylgeranylation Mediates Sensitivity to CHOP\_induced Cell Death of DLBCL Cell Line; Ageberg M, Rydström K, Lindén O, Linderöth J, Jerkeman M, Drott K, Exp Cell Res. 2011 May; 317(8):1179\_91
9. CD40 is a Potential Marker of Favourable Prognosis in Patients with Diffuse Large B\_cell Lymphoma Treated with Immunochemotherapy; Rydström K, Linderöth J, Nyman H, Ehinger M, Joost P, Bendahl PO, Leppä S, Jerkeman M, Leuk Lymphoma. 2010 Sept; 51(9):1643\_8
10. Prognostic Impact of Protein Kinase C beta II Expression in R\_CHOP\_treated Diffuse Large B\_cell Lymphoma Patients; Riihijärvi S, Koivula S, Nyman H, Rydström K, Jerkeman M, Leppä S, Mod Pathol. 2010 May; 23(5):686\_93

## Projects

### Memberships

Svensk Onkologisk Förening Svensk Förening för Hematologi

### Other Relevant Information

Previous co\_investigator in company sponsored and academic clinical trials: GCT 3013\_02; NCT04663347; Genmab, Abbvie Polar Bear; NCT04332822; Roche Valeria; NCT03505944; Abbvie, Celgene BI\_1206; NCT03571568; BioInvent International SAKK 35/14; NCT02451111; Janssen Triangle; NCT02858258; Janssen Enrich; CRUK/14/26; Janssen Iliad; NCT03576443; Gilead Preben; NCT02678299; CTI Life Science and Servier International Shine; NCT01776840; Janssen Keynote 087; NCT02453594; Merck Bio\_Chic; NCT03293173; academic